Similar to PDA patients, anti-PD-L1 or anti-PD-1 monotherapy is ineffective in KPC mouse models and provides minimal benefit in survival or tumor regression even in animal models with a model neoantigen (23, 82, 83, 87, 90, 101, 103, 118, 133, 134). Here, RPL17 is linked to Patent ductus arteriosus.